RUXOLITINIB

SynDRA canonical compound SYN0027250 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx
Primary target(s)	JAK1 \| JAK2 \| JAK3 \| TYK2
Mechanism of action	JAK inhibitor
Indication	myelofibrosis \| polycythemia vera
Disease area	hematologic malignancy \| hematology

All known targets

jakafi
INCB 018424
ruxolitinib phosphate
jakavi
Ruxolitinib, s-
S-RUXOLITINIB
(R)-RUXOLITINIB
INC-424
INC424
INCB-018424
INCB-018424 SALT
INCB-18424
INCB018424
INCB018424 (RUXOLITINIB)
INCB018424(R)-RUXOLITINIB
INCB18424
Jakafi
Jakavi
RUXOLITINIB (INCB018424)
Ruxolitinib phosphate
S-
Ruxolitinib (JAK inhibitor)
Ruxolitinib (phosphate)
(R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate
UNII-436LRU32H5
Ruxolitinib phosphate salt
Ruxolitinib phosphate(INCB018424)
CHEBI:66917
436LRU32H5
J-501793
(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate
Ruxolitinib phosphate [USAN]
Jaka
Ruxolitinib (INCB018424)
(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H -pyrazol-1-yl)-3-cyclopentylpropanenitrile
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile
82S8X8XX8H